Celebrating a year of immunotherapy/cell and gene therapy in Blood Advances DOI Creative Commons
Catherine M. Bollard, Andrew S. Weyrich

Blood Advances, Journal Year: 2024, Volume and Issue: 8(24), P. 6334 - 6336

Published: Dec. 24, 2024

Language: Английский

Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy DOI Creative Commons

Fatemeh Dehghan,

Yekta Metanat,

Mandana Askarizadeh

et al.

Frontiers in Cell and Developmental Biology, Journal Year: 2025, Volume and Issue: 12

Published: Feb. 11, 2025

Currently, CAR-T cell therapy is known as an efficacious treatment for patients with relapsed/refractory hematologic malignancies. Nonetheless, this method faces several bottlenecks, including low efficacy solid tumors, lethal adverse effects, high cost of autologous products, and the risk GvHD in allogeneic settings. As a potential alternative, CAR-NK can overcome most limitations provide off-the-shelf, safer, more affordable product. Although published results from preclinical clinical studies cells are promising, bottlenecks must be unlocked to maximize effectiveness therapy. These include vivo persistence, trafficking into tumor sites, modest sensitivity immunosuppressive microenvironment. In recent years, advances gene manipulation tools strategies have laid groundwork current This review will introduce existing discuss their advantages disadvantages. We also explore how these enhance therapy’s safety efficacy.

Language: Английский

Citations

3
Advancing Natural Killer Cell Therapy: Genetic Engineering Strategies for Enhanced Cancer Immunotherapy DOI Open Access
Joo Dong Park, Ha Eun Shin,

Y. An

et al.

Annals of Laboratory Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 8, 2025

Joo Dong Park, M.S., Ha Eun Shin, Ph.D., Yeon Su An, B.S., Hye Jung Jang, Juwon Se-Na Kim, Chun Gwon and Wooram Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2024.0380

Citations

2
Advances in CAR-NK cell therapy for hematological malignancies DOI Creative Commons
Rui Yang,

Yun Yang,

Rui Liu

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: June 28, 2024

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized the treatment of hematological malignancies, demonstrably improving patient outcomes and prognosis. However, its application introduced new challenges, such as safety concerns, off-target toxicities, significant costs. Natural killer (NK) cells are crucial components innate immune system, capable eliminating tumor without prior exposure to specific antigens or pre-activation. This inherent advantage complements limitations cells, making CAR-NK a promising avenue for immunotherapy. In recent years, preclinical clinical studies have yielded preliminary evidence supporting efficacy in paving way future advancements review aims succinctly discuss characteristics, therapeutic progress, potential challenges associated with therapy.

Language: Английский

Citations

5
A mechanistic, functional, and clinical perspective on targeting CD70 in cancer DOI Creative Commons
Sandeep Kumar,

Sowdhamini Mahendiran,

Rakesh Sathish Nair

et al.

Cancer Letters, Journal Year: 2024, Volume and Issue: 611, P. 217428 - 217428

Published: Dec. 24, 2024

The oncoimmunology research has witnessed notable advancements in recent years. Reshaping the tumor microenvironment (TME) approach is an effective method to improve antitumor immune response. T cell-mediated response crucial for favorable therapeutic outcomes several cancers. United States Food and Drug Administration (FDA) approved checkpoint inhibitors (ICIs) targeting proteins (ICPs) expressed various hematological solid malignancies. ICPs are cell co-inhibitory molecules that block activation and, thus, Currently, most of FDA-approved ICIs antagonistic antibodies programmed death-ligand 1 (PD-L1), death protein (PD-1), cytotoxic T-lymphocyte-associated 4 (CTLA-4). In contrast ICPs, costimulatory required activation, expansion, effector function. However, abrupt expression these tumors presents a concern One molecules, cluster differentiation 70 (CD70), emerged as druggable target malignancies due its role function evasion. present review describes CD70, factors affecting CD70 expression, physiological clinical relevance current approaches

Language: Английский

Citations

5
The key role of immunomodulatory cytokines for the development of novel NK cell-based cancer therapies DOI

A.A. Câmara,

Diego Barriales, Ainara Azueta Etxebarría

et al.

International review of cell and molecular biology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

0
Accelerating the clinical translation of CD70-targeted chimeric antigen receptor-based cell therapies in oncology: A comprehensive clinical investigation panorama analysis based on the Trialtrove database DOI
Yuning Wang,

Shuhang Wang,

Ning Li

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217510 - 217510

Published: Feb. 1, 2025

Language: Английский

Citations

0
Practical microenvironment classification in diffuse large B cell lymphoma using digital pathology DOI Creative Commons
Yuqing Wang, Shuo Wang, Hongmei Yi

et al.

Cell Reports Medicine, Journal Year: 2025, Volume and Issue: unknown, P. 102030 - 102030

Published: March 1, 2025

Language: Английский

Citations

0
Emerging Role of Chimeric Antigen Receptor-Natural Killer Cells for the Treatment of Hematologic Malignancies DOI Open Access
Ugo Testa, Germana Castelli, Elvira Pelosi

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(9), P. 1454 - 1454

Published: April 26, 2025

The clinical use of T lymphocytes engineered with chimeric antigen receptors (CARs) has revolutionized the treatment patients refractory or relapsed hematological malignancies. CAR natural killer (CAR-NK) cells are NK CARs to specifically target cell antigens expressed on membrane tumor cells. CAR-NK could offer some advantages respect CAR-T cells, related their specific and innate anti-tumor activity, availability as an “off shelf” cellular therapy, reduced costs, improved safety. Promising efficacy CAR-Nk therapy was observed in trials based However, date, experience been preliminary, evaluation only a limited number patients. Furthermore, by short persistence these suboptimal cytotoxic activity preparations. Therefore, studies enrollment is required carefully assess confirm safety malignancies compare allogeneic

Language: Английский

Citations

0
The Pan-Cancer Analysis Uncovers the Prognostic and Immunotherapeutic Significance of CD19 as an Immune Marker in Tumor DOI Creative Commons

Lanyi Wei,

Jingjing Meng,

Danfeng Xiang

et al.

International Journal of General Medicine, Journal Year: 2024, Volume and Issue: Volume 17, P. 2593 - 2612

Published: June 1, 2024

Background: The specific cytotoxic effects of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy have led to impressive outcomes in individuals previously treated for B-cell malignancies. However, the biological role CD19(+) target cells, which exert antitumor immunity against some solid tumors, remains be elucidated. Methods: We collected information regarding level CD19 mRNA and protein expression from various databases including Cancer Genome Atlas (TCGA), Tumor Immune Estimation Resource (TIMER), Genotype-Tissue Expression (GTEx), Human Protein (HPA) both tumor normal samples. To evaluate patient's prognosis according expression, a Kaplan-Meier (KM) analysis univariate Cox regression were performed. Furthermore, using Stromal Cells Malignant Tissues Using Data (ESTIMATE) algorithm, we estimated ratio immune cells infiltrating malignant tissues. Afterward, GSCALite repository was employed vulnerability tumors expressing drugs used chemotherapy. validate results clinical samples certain cancer types, immunohistochemistry then Results: Most types exhibited differently, apart colon adenocarcinoma (COAD). early diagnostic value has been demonstrated 9 different overexpression potential extend survival duration patients. Multiple showed positive correlation between mutation burden (TMB), microsatellite instability (MSI), ESTIMATE score. direct association discovered infiltration particularly cases breast invasive carcinoma (BRCA). Moreover, is highly sensitive variety chemotherapy drugs. Conclusion: study reveals as predictive biomarker immunotherapies. Keywords: CD19, pan-cancer, prognosis, infiltration,

Language: Английский

Citations

1
Chimeric antigen receptor natural killer cell therapy: A systematic review of preclinical studies for hematologic and solid malignancies DOI

arezoo karamivandishi,

Afshin Hatami,

Mohammad Masoud Eslami

et al.

Human Immunology, Journal Year: 2024, Volume and Issue: 86(1), P. 111207 - 111207

Published: Dec. 12, 2024

Language: Английский

Citations

0